You bet recently that DCVax-l could not be approved this year, and now you’re stating DCVax-l could be approved this year. Please take your profile and your inquirig profile and scram kid.
DR. Ashkan stated “a few months” from submission. There are new improved processes to speed approval at MHRA for high impact therapies in 2024. There is no reason to suspect DCVax-l will not be approved slightly ahead, equal to, or slightly behind Dr. Ashkan’s assessment. DCVax-l is considered a potential high impact therapy for GBM.